Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL LeukemiaShellaina J.V. Gordon, Mark A. Dawson, Jeffrey R. White et al.|Cancer Discovery|2025Cited by 20
Abstract 1130: First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER+ breast cancer with KAT6A dysregulationShikhar Sharma, Thomas A. Paul, Jay H. Chung et al.|Cancer Research|2021Cited by 14
Catalytic inhibition of KAT6/KAT7 enhances the efficacy and overcomes primary and acquired resistance to Menin inhibitors in MLL leukaemiaShellaina J.V. Gordon, Mark A. Dawson, Florian Perner et al.|bioRxiv (Cold Spring Harbor Laboratory)|2024Cited by 5
First-in-class KAT6A/KAT6B inhibitor CTx-648 (PF-9363) demonstrates potent anti-tumor activity in ER plus breast cancer with KAT6A dysregulation.Shikhar Sharma, Thomas A. Paul, Jay H. Chung et al.|Cancer Research|2021Cited by 1
Supplementary Figures S1-8 from Catalytic Inhibition of KAT6/KAT7 Enhances the Efficacy and Overcomes Primary and Acquired Resistance to Menin Inhibitors in MLL LeukemiaShellaina J.V. Gordon, Mark A. Dawson, Florian Perner et al.|Unknown|2025Cited by 0